PMVP PMV Pharmaceuticals, Inc
XNAS 1.13 DelayedStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
PMVP
$1.13
—
Key stats
$1.13
- 52-Week Range
- $1.02 – $1.91
- YTD
- -8.13%
- Straddle Price
- $2.15
- P/C Vol Ratio
- 0.00
- Market Cap
- $0.1B
- Open
- $1.26
- Day Range
- $1.10 – $1.28
- Volume
- 648,579
- Prev Close
- $1.27
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.08 |
| Cost of Equity (CAPM) | 10.90% (VRP-adj) |
| WACC | 10.97% |
| Volatility Risk Premium | +494.2pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -105.2% |
| Book / Price | 147.7% — banking bias active (P/B is primary) |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $1.38 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $1.44 |
| Bollinger Width / SMA20 | 3721.5% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: ABT, NVS, PFE
(SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$5.86
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 39.5× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 19.2× · 3 peers |
| Peer P/B | $5.86 | 100% | median 3.5× · 3 peers |
| Peer P/S | n/a | 0% | median 3.9× · 3 peers |
| Market Anchor (SMA50) | $1.38 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.1B
- Employees
- 54
- List Date
- 2020-09-25
- CIK
- 0001699382
- Next Earnings
- 2026-11-11 (Pre-Market)
- EPS Forecast
- ($0.31) (3 est.)
- Headquarters
- Princeton, NJ
- Homepage
- https://www.pmvpharma.com
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -30.68% | -31.80% | -3.30% | -43.59% | -7.19% | -12.20% | -21.46% |
| Feb | 5.35% | -0.81% | -12.82% | 3.35% | -4.86% | 60.38% | 8.43% |
| Mar | -5.89% | 25.05% | -22.94% | -9.33% | -17.42% | -31.11% | -10.27% |
| Apr | 2.40% | -28.16% | -0.86% | 1.12% | -1.98% | 4.51% | -3.83% |
| May | 1.50% | -23.78% | 15.05% | -2.15% | -12.18% | -13.67% | -5.87% |
| Jun | 8.51% | 21.48% | 14.86% | -6.36% | 20.87% | 8.94% | 11.38% |
| Jul | 1.28% | -3.42% | 4.47% | 5.06% | 35.24% | -10.84% | 5.30% |
| Aug | -11.77% | -3.13% | 9.39% | -1.26% | 0.00% | 8.04% | 0.21% |
| Sep | -1.29% | -16.11% | -16.12% | -5.70% | -6.04% | 29.46% | -2.63% |
| Oct | -21.89% | 2.84% | -74.58% | 8.67% | 3.68% | -35.43%* | -19.45% |
| Nov | -11.15% | -20.86% | 15.66% | -0.61% | -5.71% | -- | -4.53% |
| Dec | 15.56% | -8.90% | 29.17% | -10.65% | -3.10% | -- | 4.42% |
| Total | -45.17% | -67.26% | -69.02% | -53.76% | -8.67% | -23.22% | -44.52% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $1.44
SMA 50: $1.38
SMA 200: $1.30
Current: $1.13
EMA 12: $1.32
EMA 26: $1.37
MACD: -0.0521 | Signal: -0.0312
BEARISH
ADX (14): 16.03
RANGE
+DI: 18.16
−DI: 32.52
Momentum Oscillators
RSI (14): 36.80
NEUTRAL
Stoch %K: 11.25
Stoch %D: 16.95
Williams %R: -94.12
Volume & Volatility
BB Upper: $1.82
BB Lower: $1.05
NEUTRAL
OBV: -6,017,617
Vol SMA 20: 837,561
Vol ROC: 62.68%
ATR: $0.12
True Range: $0.18
HV 20: 110.4%
HV 30: 98.5%
HV 60: 78.0%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary Overall Assessment: NEUTRAL (Confidence Level: 6/10) Key Drivers: PMV Pharma's collaboration with Foundation Medicine, recent pricing of oversubscribed public offering Primary Risks: Volatility regime shift, potential catalyst fatigue Investment Thesis: The stock has been trending sideways since the spring, and a potential breakout could be triggered by upcoming earnings or regulatory updates. Recent news headlines suggest a stable environment, but we must consider the possibility of unexpected events impacting the stock's price. Recent News Sentiment Impact: Neutral sentiment from recent headlines, with no significant catalysts to drive the stock's price.
Technical Analysis Trend Direction:
- Short-term (1-4 weeks): Sideways trend
- Medium-term (1-3 months): Uptrend
- Long-term (3-12 months): Bullish
Support/Resistance Levels:
- SMA 20: $1.27 (support)
- SMA 50: $1.25 (resistance)
- Upper Bollinger Band: $1.34 (resistance)
Momentum Signals:
- RSI: Neutral (54.30), no buy/sell signal
- MACD: Bullish momentum signal, above signal line
- Bollinger Bands: Neutral signal, price touching middle band
Volume Analysis:
- Volume SMA 20: 628043.96, increasing volume suggests higher volatility potential
- On-Balance Volume (OBV): -14974280.80, indicating a bearish trend in buying and selling pressure
- Volume Rate of Change: 303.62%, showing moderate volume growth
News & Sentiment Analysis Recent Headlines Summary:
- Neutral sentiment from oversubscribed public offering news
- Positive sentiment from board chair transition announcement
- Positive sentiment from full-year financial results report
- Neutral sentiment from bottom-fishing article
- Negative sentiment from Foundation Medicine collaboration announcement
- Neutral sentiment from Acrivon Therapeutics comparison
Sentiment Assessment: NEUTRAL (average sentiment from recent headlines)
Catalyst Identification:
- Earnings date not available, but potential catalyst fatigue could lead to a breakout or breakdown
- Regulatory updates may impact the stock's price
Market Narrative: The market is currently in a range-bound environment, with no significant catalysts driving the stock's price. Recent news headlines suggest a stable environment, but we must consider the possibility of unexpected events impacting the stock's price.
Risk & Volatility Assessment Beta Interpretation: Low risk (beta 0.63 vs SPY)
Volatility Regime: Current regime is low volatility
Options Market Signals:
- IV Rank: Medium
- Current IV: High
- Expected Move: $1.30 by expiration, with a potential move of $1.75 in the next week
- Volume Flow: Bullish sentiment, with more calls than puts traded
- Open Interest: Bullish sentiment, with more calls than puts held open
Downside Protection: Support levels at SMA 20 ($1.27) and lower Bollinger Band ($1.20)
Market Context & Positioning Sector Performance: PMV Pharma is in the biotechnology sector, which has been experiencing a range-bound environment recently
Institutional Activity: Moderate institutional interest, with increasing volume traded
Correlation Analysis: The stock's price movement is relatively independent of market movements (R-squared interpretation)
Relative Valuation: The stock is positioned within its trading range, with no clear directional bias
Key Levels & Action Items Critical Price Levels:
- SMA 20 ($1.27) - support
- SMA 50 ($1.25) - resistance
Breakout/Breakdown Levels:
- Upper Bollinger Band ($1.34) - potential breakout level
- Lower Bollinger Band ($1.20) - potential breakdown level
Time-Sensitive Catalysts: Earnings date not available, but potential catalyst fatigue could lead to a breakout or breakdown
Risk Management: Stop-loss levels can be set at SMA 20 ($1.27), with position sizing considerations based on volatility and market conditions.
Analysis Guidelines Compliance Data Interpretation:
- RSI: Neutral (54.30) - no buy/sell signal
- MACD: Bullish momentum signal, above signal line
- Bollinger Bands: Neutral signal, price touching middle band
News Impact Assessment: Positive news from pricing of oversubscribed public offering and board chair transition announcement Negative news from Foundation Medicine collaboration announcement
Risk Assessment Criteria: High risk (beta 0.63 vs SPY), high volatility, negative news sentiment, technical breakdown.
Output Format Compliance Objective: Present both bullish and bearish cases
Specific Data Reference: Refer to actual numbers and values from technical indicators
Highlight Conflicts: Note when technical and news signals diverge
Generated
News
All PMVP news →
Earnings History
15 of 16 under expected move
Avg Expected Move
117.67%
Avg Actual Move
5.76%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2022-05-10 | Pre-Market | 21.65% | 9.66% | 0.45x | Within |
| 2022-08-09 | Pre-Market | 21.61% | 8.06% | 0.37x | Within |
| 2023-05-10 | Pre-Market | 15.08% | 8.33% | 0.55x | Within |
| 2023-08-09 | Pre-Market | 15.91% | 27.69% | 1.74x | Exceeded |
| 2023-11-09 | Pre-Market | 36.56% | 2.15% | 0.06x | Within |
| 2024-02-29 | Pre-Market | 32.04% | 2.21% | 0.07x | Within |
| 2024-05-09 | Pre-Market | 50.00% | 2.78% | 0.06x | Within |
| 2024-08-08 | After-Close | 131.85% | 1.37% | 0.01x | Within |
| 2024-11-07 | Pre-Market | 89.43% | 7.23% | 0.08x | Within |
| 2025-03-03 | Pre-Market | 291.97% | 3.65% | 0.01x | Within |
| 2025-05-09 | Pre-Market | 78.35% | 0.12% | 0.00x | Within |
| 2025-08-07 | Pre-Market | 106.91% | 4.61% | 0.04x | Within |
| 2025-11-12 | After-Close | 633.80% | 4.23% | 0.01x | Within |
| 2026-03-06 | Pre-Market | 99.67% | 7.19% | 0.07x | Within |
| 2026-05-12 | Pre-Market | 154.68% | 2.16% | 0.01x | Within |
| 2026-08-14 | After-Close | 103.17% | 0.79% | 0.01x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
PMVP Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $2.15
7-DTE Move: $2.15
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 2
Put Volume: 0
P/C Volume: —
BULLISH
Call OI: 2
Put OI: 0
P/C OI: —
Total OI: 2
ATM Options Pricing
ATM Call: $0.38
ATM Put: $1.77
Call %: 33.2%
Put %: 157.1%
Chain Summary
Chain Volume: 591
Chain OI: 4,393
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 564.8% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$2.15Oct 26
Beta Analysis
Risk Metrics
Beta: 0.6852
Alpha: -17.00%
Correlation: 0.1231
R-Squared: 1.5%
Stock Volatility: 71.0%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own PMVP
1 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $63K | #5943 of 6285 | +5.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
PMVP Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 52,719,361 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
4 filers$369.84K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $271.08K | 73.30% | 2026-06-30 |
| 2 | Simplex Trading, LLC Custodian | $68.34K | 18.48% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $22.24K | 6.01% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $8.17K | 2.21% | 2026-06-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|
PMVP Insider Trading (Form 4)
Latest: 2026-10-05Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Matthew Joseph Eckler | Director | Grant (A) | +84,000 opt | — | EDGAR | |
| 2026-06-05 | Laurie Stelzer | Director | Grant (A) | +42,000 opt | — | EDGAR | |
| 2026-06-05 | Arnold J Levine | Director | Grant (A) | +42,000 opt | — | EDGAR | |
| 2026-06-05 | Kirsten Flowers | Director | Grant (A) | +42,000 opt | — | EDGAR | |
| 2026-06-05 | Charles M Baum | Director | Grant (A) | +42,000 opt | — | EDGAR | |
| 2026-06-05 | Carol Giltner Gallagher | Director | Mixed | +42,000 opt | — | EDGAR | |
| 2026-03-09 | Robert Ticktin | General Counsel & COO | Grant (A) | +319,270 opt | — | EDGAR | |
| 2026-03-09 | David Henry Mack | President and CEO | Grant (A) | +744,960 opt | — | EDGAR | |
| 2026-03-09 | Deepika Jalota | Chief Development Officer | Grant (A) | +303,310 opt | — | EDGAR | |
| 2026-03-09 | Michael Carulli | Chief Financial Officer | Award (A) | — | — | EDGAR | |
| 2025-10-29 | David Henry Mack | President and CEO | Exer (M) | +220,643 | $1.37 | $302.3K | EDGAR |
| 2025-10-27 | OrbiMed Capital GP V LLC | 10%+ Owner | Sell (S) | −2,000,000 | $1.52 | -$3.04M | EDGAR |
| 2025-09-12 | OrbiMed Capital GP V LLC | 10%+ Owner | Sell (S) | −1,000,000 | $1.80 | -$1.80M | EDGAR |
| 2025-07-03 | Robert Ticktin | General Counsel & COO | Sell (S) | −23,151 | $1.06 | -$24.7K | EDGAR |
| 2025-07-03 | Deepika Jalota | Chief Development Officer | Sell (S) | −33,065 | $1.06 | -$35.2K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
PMVP Insider Holdings
7 insiders · @ $1.13
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | OrbiMed Capital GP V LLC | Director | 4,975,291 | $5.62M | $62.31M | 4 | 2025-10-27 |
| 2 | David Henry Mack | President and CEO | 904,691 | $1.02M | -$1.56M | 21 | 2026-03-09 |
| 3 | Arnold J Levine | Director | 409,842 | $463.1K | -$568.3K | 11 | 2026-06-05 |
| 4 | Robert Ticktin | General Counsel & COO | 98,695 | $111.5K | -$24.7K | 2 | 2026-03-09 |
| 5 | Deepika Jalota | Chief Development Officer | 89,959 | $101.7K | -$171.0K | 12 | 2026-03-09 |
| 6 | Michael Carulli | Chief Financial Officer | 73,848 | $83.4K | -$34.4K | 6 | 2026-03-09 |
| 7 | Richard A. Heyman | Director | 975 | $1.1K | -$126.9K | 8 | 2025-06-09 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
PMVP Board & Officers
As of SEC filings through Oct 5, 2026Directors 8
- Arnold J Levine · since Sep 24, 2020
- David Henry Mack · since Sep 24, 2020
- Laurie Stelzer · since Sep 24, 2020
- Richard A. Heyman · since Sep 24, 2020
- Charles M Baum · since Apr 1, 2021
- Kirsten Flowers · since Jan 5, 2022
- Carol Giltner Gallagher · since Nov 3, 2022
- Matthew Joseph Eckler · since Oct 1, 2026
Officers 4
- David Henry Mack · President and CEO · since Sep 24, 2020
- Michael Carulli · Chief Financial Officer · since Jan 5, 2024
- Robert Ticktin · General Counsel & COO · since Apr 21, 2025
- Deepika Jalota · Chief Development Officer · listed since May 2023
Changes in the last 10 years (115)
| Oct 1, 2026 | Matthew Joseph Eckler became a director |
| Oct 27, 2025 | Orbimed Advisors LLC reported in an SEC filing no longer being a 10% owner |
| Oct 27, 2025 | OrbiMed Capital GP V LLC reported in an SEC filing no longer being a 10% owner |
| Apr 21, 2025 | Robert Ticktin became General Counsel & COO |
| Jan 5, 2024 | The company announced the departure of Winston Kung as COO, CFO in an SEC filing |
| Jan 5, 2024 | Michael Carulli became Chief Financial Officer |
| Jan 4, 2024 | The company announced the departure of Leila Alland as Chief Medical Officer in an SEC filing |
| May 15, 2023 | Deepika Jalota listed as Chief Development Officer (previously SVP, Regulatory Affairs and QA) in SEC filings |
| Nov 3, 2022 | The company announced the departure of Thilo Schroeder from the board in an SEC filing |
| Nov 3, 2022 | Carol Giltner Gallagher became a director |
| Mar 31, 2022 | Orbimed Advisors LLC no longer listed as a director in SEC filings |
| Mar 31, 2022 | OrbiMed Genesis GP LLC no longer listed as a director in SEC filings |
| Mar 31, 2022 | OrbiMed Capital GP V LLC no longer listed as a director in SEC filings |
| Jan 5, 2022 | The company announced the departure of Peter A. Thompson from the board in an SEC filing |
| Jan 5, 2022 | Kirsten Flowers became a director |
| Jul 14, 2021 | Khaled Nasr reported in an SEC filing no longer being a 10% owner |
| Jul 14, 2021 | Keval Desai reported in an SEC filing no longer being a 10% owner |
| Jul 14, 2021 | Interwest Partners X LP reported in an SEC filing no longer being a 10% owner |
| Jul 14, 2021 | InterWest Management Partners X, LLC reported in an SEC filing no longer being a 10% owner |
| Jul 14, 2021 | Gilbert H Kliman reported in an SEC filing no longer being a 10% owner |
| Jun 15, 2021 | Symmetry Group Ltd. reported in an SEC filing no longer being a 10% owner |
| Jun 15, 2021 | Marilyn Simons reported in an SEC filing no longer being a 10% owner |
| Jun 15, 2021 | James H Simons reported in an SEC filing no longer being a 10% owner |
| Jun 15, 2021 | Greenland NFP LLC reported in an SEC filing no longer being a 10% owner |
| Jun 15, 2021 | Greenland NFP B Ltd. reported in an SEC filing no longer being a 10% owner |
| Jun 15, 2021 | Greenland FP LLC reported in an SEC filing no longer being a 10% owner |
| Jun 15, 2021 | Greenland A LLC reported in an SEC filing no longer being a 10% owner |
| Jun 15, 2021 | Euclidean Capital LLC reported in an SEC filing no longer being a 10% owner |
| Jun 15, 2021 | Ashvin Chhabra reported in an SEC filing no longer being a 10% owner |
| May 7, 2021 | Marilyn Simons first listed as a 10% owner in an SEC filing |
| May 7, 2021 | James H Simons first listed as a 10% owner in an SEC filing |
| May 7, 2021 | Greenland NFP LLC first listed as a 10% owner in an SEC filing |
| May 7, 2021 | Greenland NFP B Ltd. first listed as a 10% owner in an SEC filing |
| May 7, 2021 | Greenland FP LLC first listed as a 10% owner in an SEC filing |
| May 7, 2021 | Greenland A LLC first listed as a 10% owner in an SEC filing |
| May 7, 2021 | Euclidean Capital LLC first listed as a 10% owner in an SEC filing |
| May 7, 2021 | Ashvin Chhabra first listed as a 10% owner in an SEC filing |
| Apr 28, 2021 | Symmetry Group Ltd. became a 10% owner |
| Apr 1, 2021 | Charles M Baum became a director |
| Mar 26, 2021 | Thilo Schroeder no longer listed as a 10% owner in SEC filings |
| Sep 29, 2020 | Thomas Lips reported in an SEC filing no longer being a 10% owner |
| Sep 29, 2020 | Samantha Dawson is no longer a 10% owner, per their own SEC filing |
| Sep 29, 2020 | SICAV-SIF Nextech V Oncology S.C.S. reported in an SEC filing no longer being a 10% owner |
| Sep 29, 2020 | Rajeev M. Shah reported in an SEC filing no longer being a 10% owner |
| Sep 29, 2020 | Ra Capital Management, L.p. reported in an SEC filing no longer being a 10% owner |
| Sep 29, 2020 | Philippe Detournay reported in an SEC filing no longer being a 10% owner |
| Sep 29, 2020 | Peter Kolchinsky reported in an SEC filing no longer being a 10% owner |
| Sep 29, 2020 | Orbimed Capital LLC first on file as a director |
| Sep 29, 2020 | Orbimed Capital LLC first on file as a 10% owner |
| Sep 29, 2020 | Nextech V Gp S.a R.l. reported in an SEC filing no longer being a 10% owner |
| Sep 29, 2020 | Marilyn Simons reported in an SEC filing no longer being a 10% owner |
| Sep 29, 2020 | MVA Investors, LLC reported in an SEC filing no longer being a 10% owner |
| Sep 29, 2020 | Joseph Lewis reported in an SEC filing no longer being a 10% owner |
| Sep 29, 2020 | James H Simons reported in an SEC filing no longer being a 10% owner |
| Sep 29, 2020 | Greenland NFP LLC reported in an SEC filing no longer being a 10% owner |
| Sep 29, 2020 | Greenland NFP B Ltd. reported in an SEC filing no longer being a 10% owner |
| Sep 29, 2020 | Greenland FP LLC reported in an SEC filing no longer being a 10% owner |
| Sep 29, 2020 | Greenland A LLC reported in an SEC filing no longer being a 10% owner |
| Sep 29, 2020 | Euclidean Capital LLC reported in an SEC filing no longer being a 10% owner |
| Sep 29, 2020 | Double Epiphany, LLC is no longer a 10% owner, per their own SEC filing |
| Sep 29, 2020 | Dalia Bleyer reported in an SEC filing no longer being a 10% owner |
| Sep 29, 2020 | Boxer Capital, LLC reported in an SEC filing no longer being a 10% owner |
| Sep 29, 2020 | Boxer Asset Management Inc. reported in an SEC filing no longer being a 10% owner |
| Sep 29, 2020 | Ashvin Chhabra reported in an SEC filing no longer being a 10% owner |
| Sep 29, 2020 | Alison Levine is no longer a 10% owner, per their own SEC filing |
| Sep 29, 2020 | Aaron I. Davis reported in an SEC filing no longer being a 10% owner |
| Sep 24, 2020 | Winston Kung became COO, CFO |
| Sep 24, 2020 | Thomas Lips became a 10% owner |
| Sep 24, 2020 | Thilo Schroeder became a director |
| Sep 24, 2020 | Thilo Schroeder became a 10% owner |
| Sep 24, 2020 | Samantha Dawson became a 10% owner |
| Sep 24, 2020 | SICAV-SIF Nextech V Oncology S.C.S. became a 10% owner |
| Sep 24, 2020 | Richard A. Heyman became a director |
| Sep 24, 2020 | Rajeev M. Shah became a 10% owner |
| Sep 24, 2020 | Ra Capital Management, L.p. became a 10% owner |
| Sep 24, 2020 | Philippe Detournay became a 10% owner |
| Sep 24, 2020 | Peter Kolchinsky became a 10% owner |
| Sep 24, 2020 | Peter A. Thompson became a director |
| Sep 24, 2020 | Peter A. Thompson became a 10% owner |
| Sep 24, 2020 | Orbimed Advisors LLC became a director |
| Sep 24, 2020 | Orbimed Advisors LLC became a 10% owner |
| Sep 24, 2020 | OrbiMed Genesis GP LLC became a director |
| Sep 24, 2020 | OrbiMed Genesis GP LLC became a 10% owner |
| Sep 24, 2020 | OrbiMed Capital GP V LLC became a director |
| Sep 24, 2020 | OrbiMed Capital GP V LLC became a 10% owner |
| Sep 24, 2020 | Nextech V Gp S.a R.l. became a 10% owner |
| Sep 24, 2020 | Marilyn Simons became a 10% owner |
| Sep 24, 2020 | MVA Investors, LLC became a 10% owner |
| Sep 24, 2020 | Leila Alland became Chief Medical Officer |
| Sep 24, 2020 | Laurie Stelzer became a director |
| Sep 24, 2020 | Khaled Nasr became a 10% owner |
| Sep 24, 2020 | Keval Desai became a 10% owner |
| Sep 24, 2020 | Joseph Lewis became a 10% owner |
| Sep 24, 2020 | James H Simons became a 10% owner |
| Sep 24, 2020 | Interwest Partners X LP became a 10% owner |
| Sep 24, 2020 | InterWest Management Partners X, LLC became a 10% owner |
| Sep 24, 2020 | Greenland NFP LLC became a 10% owner |
| Sep 24, 2020 | Greenland NFP B Ltd. became a 10% owner |
| Sep 24, 2020 | Greenland FP LLC became a 10% owner |
| Sep 24, 2020 | Greenland A LLC became a 10% owner |
| Sep 24, 2020 | Gilbert H Kliman became a 10% owner |
| Sep 24, 2020 | Euclidean Capital LLC became a 10% owner |
| Sep 24, 2020 | Double Epiphany, LLC became a 10% owner |
| Sep 24, 2020 | Deepika Jalota became SVP, Regulatory Affairs and QA |
| Sep 24, 2020 | David Henry Mack became a director |
| Sep 24, 2020 | David Henry Mack became President and CEO |
| Sep 24, 2020 | Dalia Bleyer became a 10% owner |
| Sep 24, 2020 | Boxer Capital, LLC became a 10% owner |
| Sep 24, 2020 | Boxer Asset Management Inc. became a 10% owner |
| Sep 24, 2020 | Ashvin Chhabra became a 10% owner |
| Sep 24, 2020 | Arnold L Oronsky became a director |
| Sep 24, 2020 | Arnold L Oronsky became a 10% owner |
| Sep 24, 2020 | Arnold J Levine became a director |
| Sep 24, 2020 | Alison Levine became a 10% owner |
| Sep 24, 2020 | Aaron I. Davis became a 10% owner |
Not reported recently (4)
- OrbiMed Genesis GP LLC · Last reported as a 10% owner in an SEC filing dated Nov 24, 2023
- Orbimed Capital LLC · Last reported as a 10% owner in an SEC filing dated Mar 31, 2022
- Peter A. Thompson · Last reported as a 10% owner in an SEC filing dated Jun 9, 2021
- Arnold L Oronsky · Last reported as a director in an SEC filing dated Oct 2, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
PMVP Proposed Insider Sales (Form 144)
Latest: 2025-10-23
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2025-10-23 | OrbiMed Private Investments V, LP | Shareholder | 1,000,000 | $1.52M | 2025-10-23 | Morgan Stanley & Co. LLC | — | EDGAR |
| 2025-09-10 | OrbiMed Private Investments V, LP | Shareholder | 2,283,654 | $3.65M | 2025-09-10 | Themis Trading LLC | — | EDGAR |
| 2023-11-22 | OrbiMed Genesis Master Fund, L.P. | Shareholder | 87,786 | $197.5K | 2023-11-22 | Themis Trading LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
4 ETFs hold PMVP
4 shown · $5.22M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $4.0M | — | 2026-09-30 |
| 2 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $1.0M | — | 2026-09-30 |
| 3 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.02% | $186,433 | $1.2B | 2026-10-23 |
| 4 | AVTM Avantis Total Equity Markets ETF | Avantis | 0.00% | $5,989 | $771.8M | 2026-10-23 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-1.49
TTM Revenue
—
TTM Net Income
$-78.34M
TTM Op. Cash Flow
$-74.99M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | — | $-18.04M | $-0.34 | $-19.68M |
| Q4 '25 | 2025-12-31 | — | $-18.04M | $-0.34 | $-17.19M |
| Q3 '25 | 2025-09-30 | — | $-21.06M | $-0.40 | $-19.82M |
| Q2 '25 | 2025-06-30 | — | $-21.21M | $-0.41 | $-18.30M |
| Q1 '25 | 2025-03-31 | — | $-17.44M | $-0.34 | $-18.27M |
| Q4 '24 | 2024-12-31 | — | $-23.00M | $-0.45 | $-16.66M |
| Q3 '24 | 2024-09-30 | — | $-19.23M | $-0.37 | $-16.84M |
| Q2 '24 | 2024-06-30 | — | $-1.21M | $-0.02 | $-1.60M |
| Q1 '24 | 2024-03-31 | — | $-15.27M | $-0.30 | $-16.18M |
| Q4 '23 | 2023-12-31 | — | $-15.76M | $-0.31 | $-12.09M |
| Q3 '23 | 2023-09-30 | — | $-16.64M | $-0.34 | $-15.66M |
| Q2 '23 | 2023-06-30 | — | $-17.44M | $-0.38 | $-12.90M |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-12
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.68
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-89.1%
ROA
-81.1%
Div Yield
0.00%
FCF Yield
-125.88%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$59.57M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
2.79M
SI % of Float
6.41%
Days to Cover
3.59
Short Vol Ratio
58.3%
Free Float
43.58M
Float %
81.7%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-05-15